ERBB2 and breast carcinoma: In this study, we used anthracycline and taxane pharmacophore‐targeted genes to establish a risk score associated with the prognosis in HER2‐negative breast cancer patients who received at least one type of anthracycline‐ and/or taxane‐based NACT.